Oxford Asset Management’s TG Therapeutics TGTX Stock Holding History

Oxford Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,631	Closed	-$287K	–	731
2025 Q4	$287K	Buy	+9,631	New	+$315K	0.1%	314
2019 Q1	–	Sell	-28,469	Closed	-$117K	–	1969
2018 Q4	$117K	Buy	+28,469	New	+$141K	﹤0.01%	1633
2016 Q3	–	Sell	-78,427	Closed	-$475K	–	857
2016 Q2	$475K	Buy	+78,427	New	+$638K	0.02%	593
2016 Q1	–	Sell	-36,873	Closed	-$443K	–	894
2015 Q4	$443K	Buy	+36,873	New	+$466K	0.01%	692

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Oxford Asset Management's TGTX Position: Q1 2026 in Review

Oxford Asset Management sold out of TG Therapeutics (TGTX) in Q1 2026, closing a stake of 9,631 shares — an estimated $287K sold.

Oxford Asset Management first reported a position in TGTX in Q4 2015 and held it in 4 quarters. The position peaked at $475K in Q2 2016. 364 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

Oxford Asset Management reported no remaining TG Therapeutics position as of Q1 2026 after selling out during the quarter.
Oxford Asset Management sold 9,631 TG Therapeutics shares in Q1 2026, an estimated $287K.
Oxford Asset Management first reported a position in TG Therapeutics in Q4 2015 and held it in 4 quarters.
Oxford Asset Management's TG Therapeutics position peaked at $475K in Q2 2016.
364 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Oxford Asset Management's 13F filing for Q1 2026, filed 15 May 2026.